| Advice You |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
Advice You - Asset Management
Different Asset Allocation Strategies Asset allocation is the process of dividing a portfolio into major asset categories suc According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product h as bonds, real estate, cash, or stocks. In doing this there are three main strategies which are: 1. Strategic asset market ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in ng 2. Tactical asset marketing 3. Market Timing Strategic asset allocation: This focuses on designing a portfoli lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. o of investments that is suitable for your needs and sticking with that allocation through all market conditions. Once an ass here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe t allocation to stocks, bond, real estate, and cash is set, it remains in place for a long period of time. Due to the market d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro lways moving up and down a strategic ass ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc et allocation will get off target over time. It is suggested that an investor should put their portfolios back on track w easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi th the original target mix from time to time, this is called re-balancing. Re-balancing keeps a portfolio in line with an inv nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically stor's goals and objectives, and helps control investment risk. Tactical asset allocation: Tactical asset marketing involved and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ forecasting asset-class returns and increasing or decreasing commitment to an asset class based on the forecast. Return pred ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi ctions may be a function of fundamental variables, for example economic variables, technical variables, forecast of inflation, ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a recent price trends, earnings or interest-rate forecasts, or a combination of several variables. A tactical asset allocation dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod is mainly based on these predictions. Tactical Asset Marketing is also known as Active Portfolio Management. Market timing: cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin This is tactical asset allocation taken to the extreme. It involves forecasting asset returns and making “all or none' asset- tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen lass bets. A market timing strategy may start the year 100 percent in Treasury bonds and end the year 100 percent in stocks. t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel No on likes losing money, and no one likes to be out of a bull market. Market timing solves both of these problems. Although ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust some investors may believe that there are strategies that will allow them to successfully weave into and out of the markets, t y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products e facts show that few people actually do so, and those people may be lucky rather than good. Market timing is not recommended . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de by the professionals. No one knows which of these three will work well. But the best bet is to keep a well-balanced multi-a elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:How To Impress At An Interview, And Land That Job
|